Affiliation:
1. Institute of Biomedical Engineering University of Toronto 200 College Street Toronto M5S3E5 Canada
2. Department of Chemical Engineering and Applied Chemistry University of Toronto 200 College St Toronto M5S3E5 Canada
3. Department of Chemical Engineering and Applied Chemistry Institute of Biomedical Engineering University of Toronto 200 College St Toronto M5S3E5 Canada
Abstract
AbstractModeling the heterogeneity of the tumor microenvironment (TME) in vitro is essential to investigating fundamental cancer biology and developing novel treatment strategies that holistically address the factors affecting tumor progression and therapeutic response. Thus, the development of new tools for both in vitro modeling, such as patient‐derived organoids (PDOs) and complex 3D in vitro models, and single cell omics analysis, such as single‐cell RNA‐sequencing, represents a new frontier for investigating tumor heterogeneity. Specifically, the integration of PDO‐based 3D in vitro models and single cell analysis offers a unique opportunity to explore the intersecting effects of interpatient, microenvironmental, and tumor cell heterogeneity on cell phenotypes in the TME. In this review, the current use of PDOs in complex 3D in vitro models of the TME is discussed and the emerging directions in the development of these models are highlighted. Next, work that has successfully applied single cell analysis to PDO‐based models is examined and important experimental considerations are identified for this approach. Finally, open questions are highlighted that may be amenable to exploration using the integration of PDO‐based models and single cell analysis. Ultimately, such investigations may facilitate the identification of novel therapeutic targets for cancer that address the significant influence of tumor‐TME interactions.
Subject
Pharmaceutical Science,Biomedical Engineering,Biomaterials